Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25490919 | 0.91 | PLAU (0.58) | MAOBPLAUPTGS2FAAHNAAA | |
| SCHEMBL7090583 | 0.84 | PTGS2 (0.53) | MAOBPTGS2TMEM97 | |
| SCHEMBL6725743 | 0.79 | PTGS2 (0.76) | PTGS2 | |
| SCHEMBL7085156 | 0.79 | TAAR1 (0.58) | PTGS2 | |
| SCHEMBL7089389 | 0.79 | MAOB (0.58) | MAOBPTGS2 | |
| SCHEMBL9308074 | 0.79 | MAOB (0.73) | MAOBSLC13A5HCAR2IDH1HSD17B2 | |
| SCHEMBL5552809 | 0.77 | MAOB (1.00) | MAOBSLC13A5HCAR2 | |
| SCHEMBL2325334 | 0.77 | PLAU (0.57) | MAOBPLAUFAAHNAAA | |
| SCHEMBL28110469 | 0.77 | CA9 (0.68) | PLAUPTGS2 | |
| SCHEMBL2943584 | 0.77 | PLAU (0.57) | MAOBPLAUFAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | MAOB 2849/4885PLAU 2604/4885SLC13A5 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.